Carbon Ion Radiotherapy for Recurrent Gliomas

NCT01166308 | Completed DMC

• 2 other identifiers: CINDERELLA2009-017352-26
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

Treatment of patients with recurrent glioma includes neurosurgical resection, chemotherapy, or radiation therapy. In most cases, a full course of radiotherapy has been applied after primary diagnosis, therefore application of re-irradiation has to be applied cautiously. With modern precision photon techniques such as fractionated stereotactic radiotherapy (FSRT), a second course of radiotherapy is safe and effective and leads to survival times of 22, 16 and 8 months for recurrent WHO grade II, III and IV tumors. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increase relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the Glioblastoma (GBM) cell line as well as the endpoint analyzed. Protons, however, offer an RBE which is comparable to photons. First Japanese Data on the evaluation of carbon ion radiation therapy for the treatment of primary high-grade gliomas showed promising results in a small and heterogeneous patient collective. In the current Phase I/II-CINDERELLA-trial re-irradiation using carbon ions will be compared to FSRT applied to the area of contrast enhancement representing high-grade tumor areas in patients with recurrent gliomas. Within the Phase I Part of the trial, the Recommended Dose (RD) of carbon ion radiotherapy will be determined in a dose escalation scheme. In the subsequent randomized Phase II part, the RD will be evaluated in the experimental arm, compared to the standard arm, FSRT with a total dose of 36 Gy in single doses of 2 Gy. Primary endpoint of the Phase I part is toxicity. Primary endpoint of the randomized part II is survival after re-irradiation at 12 months, secondary endpoint is progression-free survival.

Conditions

Glioma

Keywords

Recurrent Glioma

Outcome Measures

Primary Outcomes (1)

• Overall Survival

  at 12 months

Secondary Outcomes (1)

• Progression-free Survival

  at 12 months

Study Arms (2)

Carbon Ion Radiotherapy

EXPERIMENTAL

Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial

Radiation: Carbon Ion Radiotherapy

Standard Treatment: Fractionated Stereotacitc Radiotherapy

ACTIVE COMPARATOR

Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy

Radiation: Fractionated Stereotactic Radiotherapy (FSRT)

Interventions

Carbon Ion Radiotherapy RADIATION

Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)

Carbon Ion Radiotherapy

Fractionated Stereotactic Radiotherapy (FSRT) RADIATION

Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy

Standard Treatment: Fractionated Stereotacitc Radiotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• unifocal, supratentorial recurrent glioma
• contrast enhancement on T1-weighted MRI and/or Amino-Acid-PET-positive high-grade tumor areas
• indication re-irradiation
• age ≥ 18 years of age
• Karnofsky Performance Score ≥60
• For women with childbearing potential, (and men) adequate contraception.
• Ability of subject to understand character and individual consequences of the clinical trial
• Written informed consent (must be available before enrolment in the trial)

You may not qualify if:

• Multifocal Glioma or Gliomatosis cerebri
• refusal of the patients to take part in the study
• previous re-irradiation or prior radiosurgery or prio treatment with interstitial radioactive seeds
• time interval of \< 6 months after primary radiotherapy
• Patients who have not yet recovered from acute toxicities of prior therapies
• Known carcinoma \< 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy
• Pregnant or lactating women
• Participation in another clinical study or observation period of competing trials, respectively.

Sponsors & Collaborators

• University Hospital Heidelberg: lead

Study Sites (1)

University Hospital of Heidelberg, Department of Radiation Oncology

Heidelberg, 69120, Germany

Location

Related Publications (1)

• Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jakel O, Haberer T, Haselmann R, Unterberg A, Wick W, Debus J. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. BMC Cancer. 2010 Oct 6;10:533. doi: 10.1186/1471-2407-10-533.

  PMID: 20925951 DERIVED

MeSH Terms

Conditions

Glioma

Interventions

Heavy Ion Radiotherapy

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Radiotherapy; Therapeutics

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr. Dr. Jürgen Debus

Study Record Dates

• First Submitted: July 19, 2010
• First Posted: July 21, 2010
• Study Start: December 1, 2010
• Primary Completion: April 1, 2016
• Study Completion: April 1, 2016
• Last Updated: May 17, 2018

Record last verified: 2018-05

Locations

DE (1)